Combination of Selected Analgesics and Cox-II Inhibitors

Abstract

Combinations of certain analgesics with COX-II inhibitors, related pharmaceutical compositions, including advantageous galenical forms containing these combinations, and the use of such combinations in methods of treatment, in particular for the treatment of pain.

1 . An active ingredient combination comprising:
 at least one analgesic compound selected from the group consisting of:   (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol;   (1S,2S)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol; and
 salts of either of the foregoing with a physiologically tolerated acid; 
 and 
   at least one COX-II inhibitor.   
     
     
         2 . The active ingredient combination of  claim 1 , wherein the analgesic compound is present in the form of a hydrochloride or citrate salt. 
     
     
         3 . The active ingredient combination of  claim 1 , wherein the analgesic compound is present in the form of a free base. 
     
     
         4 . The active ingredient combination of  claim 1 , wherein the analgesic compound is present in the form of an isolated enantiomer or isolated diastereoisomer. 
     
     
         5 . The active ingredient combination of  claim 1 , wherein the analgesic compound is present in the form of a mixture of stereoisomers. 
     
     
         6 . The active ingredient combination of  claim 1 , wherein the analgesic compound is present in the form of a racemic mixture. 
     
     
         7 . The active ingredient combination of  claim 1 , wherein the analgesic compound is present in the form of a solvate. 
     
     
         8 . The active ingredient combination of  claim 7 , wherein the analgesic compound is present in the form of a hydrate. 
     
     
         9 . The active ingredient combination of  claim 1 , wherein the COX-II inhibitor is selected from the group consisting of Celecoxib, Rofecoxib, Etoricoxib, Valdecoxib, Parecoxib, Etodolac, Meloxicam and Nimesulide. 
     
     
         10 . The active ingredient combination of  claim 1 , wherein the COX-II inhibitor is Celecoxib, Rofecoxib or Meloxicam. 
     
     
         11 . A pharmaceutical formulation comprising an active ingredient combination according to  claim 1  and a suitable auxiliary substance. 
     
     
         12 . A method of alleviating pain in a mammal, said method comprising administering to said mammal an effective pain alleviating amount of an active ingredient combination according to  claim 1 . 
     
     
         13 . The method of  claim 18 , wherein said pain is neuropathic pain, acute pain, chronic pain, visceral pain, cancer pain, or inflammatory pain. 
     
     
         14 . An active ingredient combination comprising:
 at least one analgesic compound selected from the group consisting of:   (1R,2R)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol;   (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol;   (1S,2S)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol; and   (1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-[methoxy-phenyl)-cyclohexane-1,3-diol, and
 salts of any of the foregoing with a physiologically tolerated acid; 
 and 
   at least one COX-II inhibitor selected from the group consisting of selected from the group consisting of Celecoxib, Rofecoxib, Etoricoxib, Valdecoxib, Parecoxib, Etodolac and Nimesulide.   
     
     
         15 . The active ingredient combination of  claim 14 , wherein the analgesic compound is present in the form of a hydrochloride or citrate salt. 
     
     
         16 . The active ingredient combination of  claim 14 , wherein the analgesic compound is present in the form of a free base. 
     
     
         17 . The active ingredient combination of  claim 14 , wherein the analgesic compound is present in the form of an isolated enantiomer or isolated diastereoisomer. 
     
     
         18 . The active ingredient combination of  claim 14 , wherein the analgesic compound is present in the form of a mixture of stereoisomers. 
     
     
         19 . The active ingredient combination of  claim 14 , wherein the analgesic compound is present in the form of a racemic mixture. 
     
     
         20 . The active ingredient combination of  claim 14 , wherein the analgesic compound is present in the form of a solvate. 
     
     
         21 . The active ingredient combination of  claim 20 , wherein the analgesic compound is present in the form of a hydrate. 
     
     
         22 . A pharmaceutical formulation comprising an active ingredient combination according to  claim 14  and a suitable auxiliary substance. 
     
     
         23 . A method of alleviating pain in a mammal, said method comprising administering to said mammal an effective pain alleviating amount of an active ingredient combination according to  claim 14 . 
     
     
         24 . The method of  claim 23 , wherein said pain is neuropathic pain, acute pain, chronic pain, visceral pain, cancer pain or inflammatory pain.